Back to top
more

Amarin (AMRN)

(Real Time Quote from BATS)

$0.62 USD

0.62
571,979

+0.02 (2.53%)

Updated Nov 5, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.

Amarin (AMRN) Gains As Market Dips: What You Should Know

Amarin (AMRN) closed at $16.42 in the latest trading session, marking a +0.37% move from the prior day.

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Implied Volatility Surging for Amarin (AMRN) Stock Options

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?

Is (AMRN) Outperforming Other Medical Stocks This Year?

Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

Amarin (AMRN) Beats Earnings & Beats Revenues in Q2

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.

Implied Volatility Surging for Amarin (AMRN) Stock Options

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance

Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.

Company News for Jul 3, 2019

Companies In The News Are: DAL, AMRN, HRS, ADP

Amarin Rises on Priority Review for Vascepa Label Expansion

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

Options Traders Expect Huge Moves in Amarin (AMRN) Stock

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1

Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $18.99, marking a +1.06% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

Amarin (AMRN) closed at $19.75 in the latest trading session, marking a +0.71% move from the prior day.

Implied Volatility Surging for Amarin (AMRN) Stock Options

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Misses Earnings & Beats Revenues in Q4

Amarin misses earnings estimates while it beats sales in the fourth quarter of 2018.

Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.

Amarin (AMRN) Gains As Market Dips: What You Should Know

Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day.

Amarin (AMRN) Stock Moves -0.49%: What You Should Know

Amarin (AMRN) closed at $16.15 in the latest trading session, marking a -0.49% move from the prior day.

Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer

Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.